- Home
- Publications
- Publication Search
- Publication Details
Title
Recent developments and strategies of Ebola virus vaccines
Authors
Keywords
-
Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 60, Issue -, Pages 46-53
Publisher
Elsevier BV
Online
2021-07-28
DOI
10.1016/j.coph.2021.06.008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein
- (2021) John Misasi et al. IMMUNITY
- Ebola virus disease: current vaccine solutions
- (2021) Oyewale Tomori et al. CURRENT OPINION IN IMMUNOLOGY
- The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms
- (2020) Kyle O’Donnell et al. Expert Review of Vaccines
- Treatment of Ebola-related critical illness
- (2020) Peter Kiiza et al. INTENSIVE CARE MEDICINE
- Nonclinical safety assessment of repeated administration and biodistribution of ChAd3‐EBO‐Z Ebola candidate vaccine
- (2020) Camille Planty et al. JOURNAL OF APPLIED TOXICOLOGY
- Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial
- (2020) David K Clarke et al. LANCET INFECTIOUS DISEASES
- Ebola
- (2020) Heinz Feldmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector
- (2020) Sarah Sebastian et al. Vaccines
- Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field
- (2020) Sina Bavari et al. LANCET INFECTIOUS DISEASES
- Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial
- (2020) Milagritos D Tapia et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
- (2020) Andrew J Pollard et al. LANCET INFECTIOUS DISEASES
- Current Ebola Virus Vaccine Progress
- (2019) Andrea Marzi et al. BIODRUGS
- Ebola Vaccine Trials: Progress in Vaccine Safety and Immunogenicity
- (2019) Keesha M. Matz et al. Expert Review of Vaccines
- Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
- (2019) Stefanie A. Ehrhardt et al. NATURE MEDICINE
- Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates
- (2019) John J. Suschak et al. Human Vaccines & Immunotherapeutics
- Questionable efficacy of the rVSV-ZEBOV Ebola vaccine
- (2018) Wolfram G Metzger et al. LANCET
- Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector–Based Ebola Vaccine (Ad5-EBOV) Virus Titer
- (2018) Yuhua Li et al. Human Gene Therapy Clinical Development
- Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Feng-Cai Zhu et al. LANCET
- Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia
- (2017) I. V. Dolzhikova et al. Human Vaccines & Immunotherapeutics
- Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines
- (2016) Iain D. Milligan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
- (2016) Milagritos D Tapia et al. LANCET INFECTIOUS DISEASES
- Molecular mechanisms of Ebola virus pathogenesis: focus on cell death
- (2015) L Falasca et al. CELL DEATH AND DIFFERENTIATION
- Laboratory diagnosis of Ebola virus disease
- (2015) Philippe Martin et al. INTENSIVE CARE MEDICINE
- Ebola in the United States
- (2015) Robert Lindblad et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses
- (2015) Michelle Meyer et al. JOURNAL OF CLINICAL INVESTIGATION
- Ebola: translational science considerations
- (2015) Francesco Chiappelli et al. Journal of Translational Medicine
- Development of therapeutics for treatment of Ebola virus infection
- (2015) Haoyang Li et al. MICROBES AND INFECTION
- Ebola virus disease: a highly fatal infectious disease reemerging in West Africa
- (2015) Kelvin K.W. To et al. MICROBES AND INFECTION
- Treatment of Ebola Virus Disease
- (2015) Paul E. Kilgore et al. PHARMACOTHERAPY
- Human Ebola virus infection results in substantial immune activation
- (2015) Anita K. McElroy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ebola virus outbreak, updates on current therapeutic strategies
- (2015) Hatem A. Elshabrawy et al. REVIEWS IN MEDICAL VIROLOGY
- Emergence of Zaire Ebola Virus Disease in Guinea
- (2014) Sylvain Baize et al. NEW ENGLAND JOURNAL OF MEDICINE
- Could the Ebola virus matrix protein VP40 be a drug target?
- (2013) Robert V Stahelin EXPERT OPINION ON THERAPEUTIC TARGETS
- Current ebola vaccines
- (2012) Thomas Hoenen et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A limited outbreak of Ebola haemorrhagic fever in Etoumbi, Republic of Congo, 2005
- (2011) Dieudonné Nkoghe et al. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now